Filing search / Incannex Healthcare Limited / "Innovative"

PRE 14A

IXHL Incannex Healthcare Limited

31 Oct 24

Preliminary proxy

4:10pm

on advancing innovative therapies through clinical development and regulatory approval. Previously, he was the Chief Executive Officer and Managing

8-K

EX-99.1

IXHL Incannex Healthcare Limited

24 Oct 24

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

7:30am

biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced … company focused on developing innovative medicines for patients living with chronic diseases and significant unmet needs. The company is advancing

8-K

EX-99.1

IXHL Incannex Healthcare Limited

30 Sep 24

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

4:01pm

developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year financial … of 2025. About Incannex Healthcare Inc. Incannex is a clinical-stage biopharmaceutical company focused on developing innovative medicines

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases … due to their large healthcare systems, established regulatory frameworks, and high market demand for innovative therapies. By securing approvals

8-K

EX-99.1

IXHL Incannex Healthcare Limited

10 Sep 24

Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors

8:00am

Incannex Healthcare Inc. Incannex is a clinical-stage biopharmaceutical development company focused on developing innovative medicines for patients

S-1/A

7ve 3nk0a13flieu9r6l

17 Jul 24

IPO registration (amended)

8:47am

S-1

jzgwq4lzoj

3 Jul 24

IPO registration

6:29am

6-K

EX-99.1

io3kvezoksr uvq

1 Sep 23

Report of Foreign Private Issuer

12:00am

6-K

EX-99.1

k15g0

26 Apr 23

Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

9:40pm

6-K

EX-99.1

4byr4vl0ixiupcgbd

28 Nov 22

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

8:19pm

6-K

EX-99.1

86jav45zxepgooxwafo

25 Nov 22

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

6:08am

20-F

u0fqbax ytk2p

28 Oct 22

Annual report (foreign)

6:31am

20-F

EX-4.11

z4u5m1xu14pw0 qml0cu

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

abjym28chwn8i

11 Oct 22

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

6:15am

6-K

EX-99.1

pi6m1a2os7

19 Sep 22

Report of Foreign Private Issuer

9:38pm

6-K

EX-99.1

4x9t4tgxnov9 cfrg

1 Sep 22

Report of Foreign Private Issuer

6:13am

6-K

EX-99.1

56l my07f

28 Jul 22

Incannex Healthcare Quarterly Activities Report and Appendix 4C

2:35pm

6-K

EX-99.1

5d7d 4tkd4

12 May 22

Report of Foreign Private Issuer

9:25am

6-K

EX-99.1

qicuqi

28 Apr 22

Quarterly Activities Report and Appendix 4C Cash Flow Statement

6:40am